复星医药(02196.HK)控股子公司药物注册申请获国家药监局受理

阿斯达克财经04-17

复星医药(02196.HK) 公布，旗下控股子公司桂林南药股份有限公司的膦甲酸钠注射液药品注册申请，于近日获中国国家药品监督管理局受理。相关药物拟用于，获得性免疫缺陷综合症患者的巨细胞病毒性视网膜炎；以及免疫功能低下患者的耐阿昔洛韦单纯疱疹病毒性的皮肤黏膜感染。截至今年3月，集团现阶段针对该新药物的累计研发投入约417万元人民币。(js/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-04...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2428397269?lang=zh_CN&edition=full","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20170911103105061_s.JPG","is_english":false,"pubTime":"2024-04-17 17:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2428397269","market":"hk","top_or_hot":-1,"title":"复星医药(02196.HK)控股子公司药物注册申请获国家药监局受理","media":"阿斯达克财经","content":"<div>\n<p>复星医药(02196.HK) 公布，旗下控股子公司桂林南药股份有限公司的膦甲酸钠注射液药品注册申请，于近日获中国国家药品监督管理局受理。相关药物拟用于，获得性免疫缺陷综合症患者的巨细胞病毒性视网膜炎；以及免疫功能低下患者的耐阿昔洛韦单纯疱疹病毒性的皮肤黏膜感染。截至今年3月，集团现阶段针对该新药物的累计研发投入约417万元人民币。(js/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-04...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1343034/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复星医药(02196.HK)控股子公司药物注册申请获国家药监局受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复星医药(02196.HK)控股子公司药物注册申请获国家药监局受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-17 17:49 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1343034/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>复星医药(02196.HK) 公布，旗下控股子公司桂林南药股份有限公司的膦甲酸钠注射液药品注册申请，于近日获中国国家药品监督管理局受理。相关药物拟用于，获得性免疫缺陷综合症患者的巨细胞病毒性视网膜炎；以及免疫功能低下患者的耐阿昔洛韦单纯疱疹病毒性的皮肤黏膜感染。截至今年3月，集团现阶段针对该新药物的累计研发投入约417万元人民币。(js/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-04...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1343034/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0175","symbol_name":"白马股","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1343034/latest-news/AAFN","article_id":"2428397269","we_media_id":null,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20170911103105061_s.JPG"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428397269","pubTimestamp":1713347340,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"复星医药(02196.HK) 公布，旗下控股子公司桂林南药股份有限公司的膦甲酸钠注射液药品注册申请，于近日获中国国家药品监督管理局受理。相关药物拟用于，获得性免疫缺陷综合症患者的巨细胞病毒性视网膜炎；以及免疫功能低下患者的耐阿昔洛韦单纯疱疹病毒性的皮肤黏膜感染。截至今年3月，集团现阶段针对该新药物的累计研发投入约417万元人民币。(js/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-17 16:25。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","BK0175":"白马股","BK1593":"医美概念股","02196":"复星医药","BK0012":"证金概念","BK0239":"医药制造","BK0096":"民营医院","BK0188":"融资融券","BK0028":"国家队","BK1191":"制药","BK1515":"抗疫概念","BK0183":"MSCI概念","BK0060":"抗癌","BK0187":"一线龙头","BK0196":"行业龙头"},"translate_title":"Fosun Pharma (02196. HK) Holding Subsidiary's Drug Registration Application Accepted by the State Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"复星医药(02196.HK) 公布，旗下控股子公司桂林南药股份有限公司的膦甲酸钠注射液药品注册申请，于近日获中国国家药品监督管理局受理。相关药物拟用于，获得性免疫缺陷综合症患者的巨细胞病毒性视网膜炎；以及免疫功能低下患者的耐阿昔洛韦单纯疱疹病毒性的皮肤黏膜感染。截至今年3月，集团现阶段针对该新药物的累计研发投入约417万元人民币。(js/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-17 16:25。)AASTOCKS新闻","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428397269"}